Ying-hong Wang

发表

Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

J. Wagner, P. Jumes, J. Schwartz, 2011, Cardiovascular therapeutics.

Variability in Human In Vitro Enzyme Kinetics.

B. Ma, C. Gibson, Ninad Varkhede, 2021, Methods in molecular biology.

Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression

N. Chalasani, T. Skaar, J. Gorski, 2005, Clinical pharmacology and therapeutics.

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP 3 A 4 AND CYP 3 A 5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005 .

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005, Drug Metabolism and Disposition.

Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

J. Wagner, K. Lasseter, T. Marbury, 2011, Journal of clinical pharmacology.

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Ying-hong Wang, W. Ni, M. Cai, 2022, Frontiers in Oncology.

Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations

Justin C. Earp, Jiang Liu, Shiew-Mei Huang, 2021, CPT: pharmacometrics & systems pharmacology.

Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve

D. Henze, C. Regan, Yuxing Li, 2022, Channels.

Variability in human in vitro enzyme kinetics.

Christopher R. Gibson, Ying-hong Wang, 2014, Methods in molecular biology.

Induction of hepatoma carcinoma cell apoptosis through activation of the JNK-nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-ROS self-driven death signal circuit.

Kewu Zeng, P. Tu, Yong Jiang, 2014, Cancer letters.

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Andy Z. X. Zhu, Yuan Chen, I. Poggesi, 2020, Clinical pharmacology and therapeutics.

Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

David Moore, Yuan Chen, Louis Leung, 2016, Drug Metabolism and Disposition.

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

S. Hall, Ying-Hong Wang, David R. Jones, 2004, Drug metabolism and disposition: the biological fate of chemicals.

PREDICTION OF CYTOCHROME P 450 3 A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES

S. Hall, David R. Jones, Ying-hong Wang, 2004 .

PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling

Karsten Menzel, G. Hartmann, Ying‐Hong Wang, 2018, Clinical pharmacology and therapeutics.

Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors

Ying-Hong Wang, Ying-hong Wang, 2010, Drug Metabolism and Disposition.

Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways.

Yong Jiang, P. Tu, Zhi-zhong Ma, 2013, Toxicology and applied pharmacology.

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

J. Wagner, M. Gutierrez, J. Schwartz, 2009, American journal of therapeutics.

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice.

Edward C Sherer, John Majercak, Deping Wang, 2017, Bioorganic & medicinal chemistry letters.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites

S. Grimm, D. Jones, S. Hall, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go?

John A Wagner, Arthur J Bergman, J. Chodakewitz, 2011, Journal of clinical pharmacology.

The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir.

D. Mehrotra, R. Mogg, M. Robertson, 2019, Pharmacogenomics.

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

J. McCrea, G. Hartmann, Carolyn R Cho, 2023, Clinical and translational science.

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model.

Michael A Rossi, D. Henze, J. Majercak, 2017, Bioorganic & medicinal chemistry letters.

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

J. Wagner, M. Gutierrez, J. Schwartz, 2009, American journal of therapeutics.